✨ Dibucaine Hydrochloride (CAS 61-12-1) | High-Purity Local Anesthetic & Sodium Channel Inhibitor ✨
🧪 Product Overview
Dibucaine Hydrochloride (CAS 61-12-1), also known as Cinchocaine HCl, is a potent amide-type local anesthetic and sodium channel blocker with the molecular formula C₂₀H₂₉N₃O₂·HCl and a molecular weight of 379.92. This white crystalline powder (purity ≥99%) is widely used for its rapid-acting nerve-blocking properties, offering effective pain relief in clinical and research settings. It exhibits strong lipid solubility, enabling deep tissue penetration and prolonged anesthetic effects.
Key Functions:
Induces local anesthesia for surgical and diagnostic procedures.
Inhibits voltage-gated sodium channels in neurophysiological studies.
Serves as a pharmaceutical intermediate or reference standard.
Target Industries: Pharmaceutical manufacturing, biomedical research, and clinical applications.
⭐ Key Advantages
| 🔹 Ultra-High Purity | 🔹 Rapid Onset | 🔹 Stability |
|---|
| ≥99% HPLC-certified | Action within 5–10 minutes | Stable at room temperature |
| Batch-specific COA | Duration: 2–3 hours | Moisture-proof packaging |
🏭 Applications
Surgical Anesthesia: Topical or injectable formulations for minor procedures.
Neurological Research: Sodium channel inhibition studies in cellular models.
Pain Management: Relief for acute or chronic neuropathic pain.
📊 Quality Assurance
Testing Standards: Validated via HPLC, NMR, and FTIR spectroscopy.
Packaging: Available in 1g–25kg customizable batches (aluminum foil bags or bulk drums).
Storage: Sealed in dry, cool conditions to maintain integrity.
📈 Market Insights
The global local anesthetics market is projected to grow at 5.8% CAGR (2025–2030), driven by rising demand for non-opioid pain management solutions. Dibucaine remains critical in niche neurological research, with Asia-Pacific emerging as a key production hub due to cost-efficient synthesis and advanced R&D infrastructure.
China
